Clinical trial
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First…
NCT00193037 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193037 |
|---|---|
| Title | Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer |
| Official title | A Phase II Randomized Crossover Study Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Ortho Biotech, Inc. Industry Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Liposomal Doxorubicin, Docetaxel |
| Enrollment | 102 |
| Start date | Feb 1, 2001 |
| Primary completion | Dec 1, 2008 |
| Completion | Nov 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: